Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
Punglia RS, Jiang W, Lipsitz SR, Hughes ME, Schnitt SJ, Hassett MJ, Nekhlyudov L, Achacoso N, Edge S, Javid SH, Niland JC, Theriault RL, Wong YN, Habel LA. Punglia RS, et al. Among authors: jiang w. Breast Cancer Res Treat. 2018 Feb;167(3):751-759. doi: 10.1007/s10549-017-4553-5. Epub 2017 Oct 28. Breast Cancer Res Treat. 2018. PMID: 29079937
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS. O'Shaughnessy J, et al. Among authors: jiang w. Breast Cancer Res Treat. 2018 Aug;170(3):547-557. doi: 10.1007/s10549-018-4770-6. Epub 2018 Apr 19. Breast Cancer Res Treat. 2018. PMID: 29675680 Clinical Trial.
16,193 results
You have reached the last available page of results. Please see the User Guide for more information.